Mold-Tek Packaging Q3 FY26 Call: Discusses Strong Volume Growth, Vibe MOU, and Pharma Expansion
Mold-Tek Packaging's Q3 FY26 call revealed EBITDA up 20% and sales up 12% for nine months. Q3 saw 6% volume growth and 14% EBITDA growth. The company anticipates 12-15% volume growth going forward and aims to cross ₹1,000 crore revenue in FY27. Pharma segment target is ₹50-55 crore for FY27. Capex for FY27 is ₹80-85 crore.
The announcement details financial performance, strategic partnerships (Vibe, Swiggy), significant operational changes (unit consolidation), and future growth projections across key segments like Pharma and FMCG, which are material to investors.
The company reported positive growth in EBITDA and sales, expressed confidence in future volume growth, and outlined expansion plans in the Pharma segment. The outlook for FY27 is optimistic with revenue and EBITDA growth targets.
Mold-Tek Packaging Limited held an Earnings Conference Call on February 9, 2026, to discuss their Q3 FY26 results. During the call, Chairman and Managing Director, Mr. J. Lakshmana Rao, highlighted that EBITDA was up by approximately 20% and sales by 12% in value terms for the nine months compared to the previous year. For Q3 FY26, sales volumes increased by 6% year-on-year, with EBITDA also rising by 14%. The company anticipates returning to a normal volume growth of 12-15% in Q4 FY26 and Q1 FY27, driven by a strong order book. Significant operational efficiencies are expected from the consolidation of manufacturing units in Hyderabad from March onwards, reducing the number of units from five to two.
The company also provided updates on its MOU with Vibe Generation for developing product patents for closures and other applications. Pilot molds are expected to be ready by the end of February and March, with commercial feasibility testing to follow. Commercial production is anticipated by the end of Q1 FY27, with potential sales in both European and Indian markets. The Vibe partnership is expected to contribute tens of crores over the next year.
In the Pharma segment, over 25 clients have been audited and cleared for production. While commercial pickup has started with less than half of these clients, the rest are expected to commence in the coming months, ensuring good volume growth. The company projects achieving INR35 crores in the Pharma segment for the full year FY26 and has set a target of INR50-55 crores for FY27, representing a 40-45% growth. The company also discussed challenges in the lubricant segment, including a 10% volume dip in Q3 FY26, partly due to losing the BPCL tender and a strategic decision to move away from low-grade lubricants. However, the addition of Veedol is expected to help recover some of this loss.
Looking ahead, Mold-Tek Packaging aims to cross INR1,000 crores in top-line revenue for FY27, with an internal target of 12-15% volume growth. EBITDA is projected to reach INR170 crores for FY26 and comfortably cross INR200-210 crores in FY27. PAT is expected to grow around 20% annually, reaching INR73-75 crores for FY26 and similar growth anticipated for FY27. Capex for FY27 is estimated at INR80-85 crores, with a significant portion allocated to the Pharma segment for new product development like eye droppers and nasal sprays. The company also highlighted a new MOU with Swiggy for restaurant packs, expected to yield margins similar to the Food and FMCG segment.
What to do with a filing like this
Mold-Tek Packaging Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mold-Tek Packaging Limited. Read the original for the full detail.